Who are Vonoprazan-Amoxicillin with Berberine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vonoprazan-amoxicillin-with-berberine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vonoprazan-Amoxicillin with Berberine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vonoprazan-Amoxicillin with Berberine (Vonoprazan-Amoxicillin with Berberine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H. pylori eradication therapy (combination: proton pump inhibitor alternative + beta-lactam antibiotic + herbal antimicrobial). Area: Gas

marketed H. pylori eradication therapy (combination: proton pump inhibitor alternative + beta-lactam antibiotic + herbal antimicrobial) H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); multiple H. pylori targets (berberine) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vonoprazan-Amoxicillin with Berberine (Vonoprazan-Amoxicillin with Berberine) — Nanjing First Hospital, Nanjing Medical University. This combination uses vonoprazan to suppress gastric acid, amoxicillin to kill H. pylori bacteria, and berberine as an adjunctive antimicrobial and anti-inflammatory agent for H. pylori eradication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vonoprazan-Amoxicillin with Berberine TARGET	Vonoprazan-Amoxicillin with Berberine	Nanjing First Hospital, Nanjing Medical University	marketed	H. pylori eradication therapy (combination: proton pump inhibitor alternative + beta-lactam antibiotic + herbal antimicrobial)	H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); multiple H. pylori targets (berberine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H. pylori eradication therapy (combination: proton pump inhibitor alternative + beta-lactam antibiotic + herbal antimicrobial) class)

Nanjing First Hospital, Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vonoprazan-Amoxicillin with Berberine — Competitive Intelligence Brief. https://druglandscape.com/ci/vonoprazan-amoxicillin-with-berberine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab